This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Solving puzzles in nanotechnology: how to transform an artifact into an antidote

Published: 14 Sep 2018
Category:

The idea of a magic bullet is very compelling and attractive. Curing diseases with the precise delivery of therapeutics to the target cell or microorganism has received the attention of many laboratories around the world and has captured the imagination of writers and film directors for many years.

The possibility of engineering nanotherapeutics capable of effectively achieving these goals is the daydream of researchers everywhere. Nanomaterials are not only used in medicine; their use expands to electronics, agriculture, textile production, and many other industries. Many nanomedicine products have reached the shelves, being used to either treat or diagnose diseases. But one limitation of their use in medicine is their toxicity. For this reason, many efforts are under way to understand the mechanisms of nanotoxicity.

My laboratory is multidisciplinary and highly collaborative, and we focus on how nanoparticles interact with cells. One of the areas of interest in my lab includes investigating the mechanisms through which nanomaterials interact with cells in the body. This puzzle requires the knowledge of the nanoparticle’s properties and how the biological media interact with the nanomaterial. Obviously, cells play an important role in taking up the particles and processing them. For these reasons, we are firstly interested in how nanomaterials interact with cells, how they are taken up by cells, and what they do with nanomaterials such as carrying oligonucleotides. Secondly, we are interested in investigating the risks involved in the use of nanoparticles and the events they may trigger in different cells of the body. One of the risks they present relates to their small size and the way through which they can travel in the body and reach cells in many vital organs, potentially inducing toxicity.

Through the study of silver nanoparticles, we have found that they induce oxidative stress in hepatocytes. Previous studies have also found that cell death is induced by silver nanoparticles and therefore we wanted to investigate the connection between oxidative stress and cell death. In our studies we found that whilst the presence of some antioxidants mitigated silver nanoparticle-induced oxidative stress, other antioxidants didn’t. Then things started to become more interesting. Digging deeper, we found that some antioxidants can bind with silver nanoparticles. This was somewhat unexpected and a potential game changer. This finding led us to wonder, if specific antioxidants can bind directly to the nanoparticles in vitro, how does this translate in vivo? Could the binding of antioxidants to silver nanoparticles prevent toxicity? We know that silver nanoparticles lead to hepatotoxicity so, we treated rats with silver nanoparticles, one hour later we injected the antioxidant and after 24 hours we checked for the toxic effects. The result was astonishing: all signs of toxicity related to nanoparticle liver accumulation were gone. After antioxidant treatment, they were excreted in the urine. The good news was that this antioxidant is approved for human use and has been for decades.

Our work continues but is just one example of how we were able to transform an artifact into an antidote.

Then things started to become more interesting. Digging deeper, we found that some antioxidants can bind with silver nanoparticles

Comments

Blog post currently doesn't have any comments.

If you are a British Pharamcological Society member, please sign in to post comments.

About the author

Marcelo Bispo de Jesus is Group Leader of Nano-cell Interactions Lab at University of Campinas, Brazil. He received his PhD in cell biology at the University of Groningen. Dr de Jesus was granted the São Paulo Research Foundation’s Young Investigator award, before taking up a position at the University of Campinas. In his current position, Dr de Jesus leads a multidisciplinary team working in the field of nanotechnology, focusing on gene delivery and nanotoxicology